• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    ALX Oncology Holdings Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    6/12/25 4:18:45 PM ET
    $ALXO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ALXO alert in real time by email
    8-K
    false000181018200018101822025-06-112025-06-11

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

    FORM 8-K

     

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): June 11, 2025

     

    ALX ONCOLOGY HOLDINGS INC.

    (Exact name of Registrant as Specified in Its Charter)

     

     

    Delaware

    001-39386

    85-0642577

    (State or Other Jurisdiction

    of Incorporation)

    (Commission File Number)

    (IRS Employer

    Identification No.)

     

     

     

    323 Allerton Avenue,

    South San Francisco, California

    94080

    (Address of Principal Executive Offices)

    (Zip Code)

     

    Registrant’s Telephone Number, Including Area Code: (650) 466-7125

    N/A

    (Former Name or Former Address, if Changed Since Last Report)

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

    ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

    ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

    ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class

     

    Trading

    Symbol(s)

     

    Name of each exchange on which registered

    Common Stock, par value $0.001 per share

     

    ALXO

     

    The Nasdaq Global Select Market

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     


     

    Item 5.07 Submission of matters to a vote of security holders.

    ALX Oncology Holdings Inc. (the “Company”) held its Annual Meeting of stockholders (the “Annual Meeting”) on June 11, 2025. The matters voted upon at the Annual Meeting and the voting results for each proposal are set forth below.

    Proposal 1: Election of Two Class II Directors

    Name of Director

     

    For

     

    Withheld

     

    Broker Non-Votes

    Scott Garland

     

    23,602,975

     

    8,662,965

     

    11,796,795

    Barbara Klencke, M.D.

     

    30,835,565

     

    1,430,375

     

    11,796,795

    Each director nominee was duly elected to serve until the 2028 annual meeting of stockholders and until their successor is duly elected and qualified, subject to earlier resignation or removal.

    Proposal 2: Advisory Vote on the Compensation of the Company’s Named Executive Officers

    For

     

    Against

     

    Abstain

     

    Broker Non-Votes

    22,147,884

     

    8,736,683

     

    1,381,373

     

    11,796,795

    The stockholders approved, on an advisory basis, the compensation paid to the Company’s named executive officers, as disclosed in the proxy statement for the Annual Meeting.

    Proposal 3: Ratification of the Appointment of Independent Registered Public Accounting Firm

    For

     

    Against

     

    Abstain

    41,776,769

     

    59,969

     

    2,225,997

    The stockholders ratified the appointment of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2025.

    1


     

    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

     

    ALX ONCOLOGY HOLDINGS INC.

    Date: June 12, 2025

    By:

    /s/ Harish Shantharam

    Harish Shantharam

    Chief Financial Officer

     

    2


    Get the next $ALXO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ALXO

    DatePrice TargetRatingAnalyst
    3/6/2025$2.00 → $3.00Hold → Buy
    Jefferies
    12/19/2024$12.00 → $2.00Buy → Hold
    Jefferies
    3/8/2024$10.00 → $14.00Buy → Hold
    Stifel
    12/8/2023$8.00 → $18.00Hold → Buy
    Jefferies
    3/1/2022$60.00 → $36.00Buy
    Stifel
    12/22/2021$65.00 → $25.00Buy → Hold
    Jefferies
    9/30/2021$106.00Buy
    Stifel
    More analyst ratings